zimmytws / Shutterstock.com
In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review (IPR) proceedings to a pre-American Invents Act (AIA) patent isn’t unconstitutional.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Celgene, US Court of Appeals for the Federal Circuit, constitution, Coalition for Affordable Drugs, Kyle Bass, teratogenic, IPR, inter partes reviews